Recently, Frost & Sullivan (Frost & Sullivan) released the 'White Paper on the Development of China's Cellular and Gene Therapy Industry'. The report aims to analyze the current development status, industry characteristics, therapeutic areas, driving factors, and development trends of China's cellular and gene therapy (CGT) industry. It also focuses on the competitive market situation in China's pharmaceutical CGT industry, reflecting the differentiated competitive advantages of the leading enterprises in this market.
